论文部分内容阅读
目的:观察卡培他滨(希罗达)联合草酸铂作为一线方案治疗晚期大肠癌的临床疗效和可耐受性。方法: 53例晚期大肠癌患者采用希罗达1 250mg/(m2·d)口服,第1~14天,草酸铂130mg/(m2·d)静滴第1天, 21天1周期,连用2周期以上评价疗效。结果:CR8例,PR20例,总有效率(CR+PR)为52.8%。毒副作用主要为Ⅰ~Ⅱ级恶心、呕吐、腹泻、口炎、末梢神经异常及白细胞减少。结论:卡培他宾联合草酸铂治疗晚期大肠癌疗效较高,安全性好,副作用可耐受,值得进一步临床观察。
Objective: To observe the clinical efficacy and tolerability of capecitabine (Xeloda) combined with oxaliplatin as a first-line regimen in the treatment of advanced colorectal cancer. Methods: Fifty-three patients with advanced colorectal cancer were treated with Xeloda 1 250 mg / (m2 · d) orally for 1 day, 14 days and oxaliplatin 130 mg / (m2 · d) for 1 day, 21 days and 1 cycle, Evaluation of efficacy over the cycle. Results: CR8 cases and PR20 cases showed a total effective rate (CR + PR) of 52.8%. Side effects are mainly grade Ⅰ ~ Ⅱ nausea, vomiting, diarrhea, stomatitis, peripheral nerve abnormalities and leukopenia. CONCLUSION: Capecitabine and oxaliplatin combined with oxaliplatin are effective in treating advanced colorectal cancer with good safety and side effects. It is worth further clinical observation.